PDCD1 and neoplasm: Tumor-associated macrophages can impede the efficacy of checkpoint immunotherapy: in vivo imaging clearly showed that TAMs uptake anti-PD-1 monoclonal antibodies in tumor-bearing mice, thereby limiting the therapeutic antibody effect on PD1-expressing tumor-infiltrating CD8+ T cells (Arlauckas et al., 2017).